Boston Scientific Corporation

42.57+0.2600+0.61%Vol 11.94M1Y Perf 20.03%
Apr 22nd, 2021 16:00 DELAYED
BID41.80 ASK42.99
Open42.31 Previous Close42.31
Pre-Market42.45 After-Market-
 -0.12 -0.28%  - -
Target Price
43.79 
Analyst Rating
Strong Buy 1.28
Potential %
2.87 
Finscreener Ranking
★+     44.31
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★+     46.10
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★     44.16
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Market Cap60.47B 
Earnings Rating
Strong Sell
Price Range Ratio 52W %
97.66 
Earnings Date
28th Apr 2021

Today's Price Range

42.0342.80

52W Range

32.9942.80

5 Year PE Ratio Range

-86.70493.00

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
4.06%
1 Month
14.31%
3 Months
14.96%
6 Months
14.53%
1 Year
20.03%
3 Years
47.71%
5 Years
115.44%
10 Years
494.55%

TickerPriceChg.Chg.%
BSX42.570.26000.61
AAPL131.94-1.5600-1.17
GOOG2 267.92-25.3700-1.11
MSFT257.17-3.4100-1.31
XOM55.27-0.7300-1.30
WFC42.70-0.5400-1.25
JNJ165.18-1.4100-0.85
FB296.52-4.9500-1.64
GE13.410.06000.45
JPM147.37-3.1700-2.11
ValuationValueIndustryS&P 500US Markets
-511.40
3.79
7.88
38.40
44.90
1.06
-107.62
10.79
65.92B
Forward PE22.60
PEG-54.99
Financial StrengthValueIndustryS&P 500US Markets
0.90
1.80
0.38
0.62
0.80
Leverage Ratio 2.00
ProfitabilityValueIndustryS&P 500US Markets
65.10
2.80
14.20
8.90
-1.33
RevenueValueIndustryS&P 500US Markets
7.37B
5.19
2.96
6.20
Earnings HistoryEstimateReportedSurprise %
Q04 20200.310.23-25.81
Q03 20200.250.3748.00
Q02 2020-0.040.08300.00
Q01 20200.330.28-15.15
Q04 20190.440.464.55
Q03 20190.380.392.63
Q02 20190.380.392.63
Q01 20190.360.35-2.78
Earnings Per EndEstimateRevision %Trend
3/2021 QR0.30-14.29Negative
6/2021 QR0.35-7.89Negative
12/2021 FY1.53-4.97Negative
12/2022 FY1.81-1.09Negative
Next Report Date28th Apr 2021
Estimated EPS Next Report0.30
Estimates Count12
EPS Growth Next 5 Years %9.30
Volume Overview
Volume11.94M
Shares Outstanding1.42B
Trades Count61.38K
Dollar Volume558.22M
Avg. Volume9.32M
Avg. Weekly Volume9.74M
Avg. Monthly Volume6.79M
Avg. Quarterly Volume8.94M

Boston Scientific Corporation (NYSE: BSX) stock closed at 42.57 per share at the end of the most recent trading day (a 0.61% change compared to the prior day closing price) with a volume of 12.02M shares and market capitalization of 60.47B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 38000 people. Boston Scientific Corporation CEO is Michael F. Mahoney.

The one-year performance of Boston Scientific Corporation stock is 20.03%, while year-to-date (YTD) performance is 18.41%. BSX stock has a five-year performance of 115.44%. Its 52-week range is between 32.99 and 42.8, which gives BSX stock a 52-week price range ratio of 97.66%

Boston Scientific Corporation currently has a PE ratio of -511.40, a price-to-book (PB) ratio of 3.79, a price-to-sale (PS) ratio of 7.88, a price to cashflow ratio of 38.40, a PEG ratio of 2.32, a ROA of -0.36%, a ROC of 17.62% and a ROE of -0.76%. The company’s profit margin is -1.33%, its EBITDA margin is 14.20%, and its revenue ttm is $7.37 Billion , which makes it $5.19 revenue per share.

Of the last four earnings reports from Boston Scientific Corporation, there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $0.30 for the next earnings report. Boston Scientific Corporation’s next earnings report date is 28th Apr 2021.

The consensus rating of Wall Street analysts for Boston Scientific Corporation is Strong Buy (1.28), with a target price of $43.79, which is +2.87% compared to the current price. The earnings rating for Boston Scientific Corporation stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Boston Scientific Corporation has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Boston Scientific Corporation has a Buy technical analysis rating based on Technical Indicators (ADX : 9.59, ATR14 : 0.98, CCI20 : 182.02, Chaikin Money Flow : 0.35, MACD : 1.01, Money Flow Index : 85.17, ROC : 9.29, RSI : 76.82, STOCH (14,3) : 94.60, STOCH RSI : 1.00, UO : 67.78, Williams %R : -5.40), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Boston Scientific Corporation in the last 12-months were: Arthur C. Butcher (Option Excercise at a value of $173 310), Arthur C. Butcher (Sold 26 578 shares of value $1 052 852 ), Daniel J. Brennan (Option Excercise at a value of $177 897), Daniel J. Brennan (Sold 63 531 shares of value $2 415 321 ), David A. Pierce (Option Excercise at a value of $0), David A. Pierce (Sold 54 948 shares of value $2 121 049 ), Desiree Ralls-Morrison (Option Excercise at a value of $0), Desiree Ralls-Morrison (Sold 1 182 shares of value $46 098 ), Edward F. Mackey (Option Excercise at a value of $0), Eric Francis Yves Thepaut (Option Excercise at a value of $241 677), Eric Francis Yves Thepaut (Sold 28 883 shares of value $1 116 354 ), Ian T. Meredith (Option Excercise at a value of $0), Jeffrey B. Mirviss (Option Excercise at a value of $933 812), Jeffrey B. Mirviss (Sold 170 864 shares of value $6 949 592 ), Jodi Euerle Eddy (Option Excercise at a value of $0), Jodi Euerle Eddy (Sold 15 500 shares of value $604 258 ), John Bradley Sorenson (Option Excercise at a value of $0), John Bradley Sorenson (Sold 7 500 shares of value $292 971 ), Jonathan Monson (Option Excercise at a value of $0), Joseph M. Fitzgerald (Option Excercise at a value of $555 902), Joseph M. Fitzgerald (Sold 77 640 shares of value $3 164 653 ), Maulik Nanavaty (Option Excercise at a value of $118 248), Maulik Nanavaty (Sold 38 000 shares of value $1 537 164 ), Meghan Scanlon (Option Excercise at a value of $0), Michael F. Mahoney (Option Excercise at a value of $0), Michael F. Mahoney (Sold 259 207 shares of value $9 087 227 ), Scott Olson (Option Excercise at a value of $0), Scott Olson (Sold 1 400 shares of value $52 283 ), Wendy Carruthers (Option Excercise at a value of $0), Wendy Carruthers (Sold 10 200 shares of value $399 401 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
15 (83.33 %)
16 (84.21 %)
15 (88.24 %)
Moderate Buy
1 (5.56 %)
1 (5.26 %)
1 (5.88 %)
Hold
2 (11.11 %)
2 (10.53 %)
1 (5.88 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.28
Strong Buy
1.26
Strong Buy
1.18

Boston Scientific Corporation

Boston Scientific produces less-invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract tests, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.

CEO: Michael F. Mahoney

Telephone: +1 508 683-4000

Address: 300 Boston Scientific Way, Marlborough 01752-1234, MA, US

Number of employees: 38 000

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

58%42%

Bearish Bullish

67%33%

Bearish Bullish

68%32%

News

Stocktwits